L3VLUP
ProSign in

QTRX · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

QTRXJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • QTRX
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterQTRXJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 20203 holders, $53m32 holders, $26.6bn
Q1 20214 holders, $131m31 holders, $25.3bn
Q2 20213 holders, $150m37 holders, $25.6bn
Q3 20213 holders, $135m40 holders, $24.1bn
Q4 20213 holders, $116m33 holders, $25.2bn
Q1 20223 holders, $78m35 holders, $28.2bn
Q2 20222 holders, $14m33 holders, $26.9bn
Q3 20222 holders, $7.1m36 holders, $25.4bn
Q4 20222 holders, $24m35 holders, $27.6bn
Q1 20232 holders, $7.5m42 holders, $24.5bn
Q2 20232 holders, $15m38 holders, $25.0bn
Q3 20233 holders, $39m37 holders, $18.9bn
Q4 20233 holders, $27m31 holders, $19.0bn
Q1 20242 holders, $26m32 holders, $19.7bn
Q2 20242 holders, $9.4m35 holders, $20.4bn
Q3 20241 holders, $8.2m28 holders, $22.3bn
Q4 20241 holders, $6.7m37 holders, $20.4bn
Q1 20251 holders, $3.9m32 holders, $20.5bn
Q2 20251 holders, $4.0m31 holders, $18.4bn
Q3 2025none listed holders, n.a.32 holders, $23.7bn
Q4 20252 holders, $3.7m29 holders, $27.8bn
Q1 20261 holders, $4.6m34 holders, $35.6bn
Q2 20261 holders, $12m33 holders, $39.1bn
QTRX

Quanterix Corp

Holders
0
Reported value
$0
Buyers
0
Sellers
1

Not ranked this quarter: its new positions are allocations in a new listing.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
JNJ

Johnson & Johnson

Holders
32
Reported value
$23.7bn
Buyers
17
Sellers
13

Breadth +4 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only QTRX (0)

None.

Only JNJ (32)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, and 7 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →